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We present here successful treatment with bisphosphonate pamidronate of a 54-year-
old patient with advanced ovarian cancer and humoral hypercalcemia of malignancy,
followed by cytoreductive surgery and postoperative chemotherapy.  Concentration of
serum calcium increased to 16.8 mg/dL and parathyroid hormone-related protein
(PTHrP)-intact was remarkably elevated.  Interestingly, the 1,25-dihydroxyvitamin D
(1,25-DHD) was high in this case.  Treatment with bisphosphonate pamidronate was
effective for the improvement of hypercalcemia so that she could undergo optimal
surgery followed by postoperative chemotherapy.  The histochemical examination of
PTHrP using anti-human monoclonal antibody showed positive staining in the cancer
cells of the ovary.
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Hypercalcemia is frequently associated with
malignancy, and is often a major contributor to
morbidity and complicates clinical manage-
ment (Allan et al., 1984; Fujino et al., 1992).
Humoral hypercalcemia of malignancy (HHM)
is defined as hypercalcemia in malignant tumor
patients without bone metastasis (Martin et al.,
1991).  Parathyroid hormone-related protein
(PTHrP) is one main causative substance for
HHM.  HHM is commonly found in squamous
cell carcinoma, renal cell carcinoma, and
hematopoietic malignancies (Honda et al.,
1988; Kitazawa et al., 1991; Gotoh et al., 1993).
There are a few reports of HHM in patients with
ovarian cancer (Kitazawa et al., 1997).
Bisphosphonate pamidronate strongly
inhibits bone resorption, probably by exerting a
cytotoxic effect on mature osteoclasts and im-
pairing recruitment and maturation of osteo-
clast-precursor cells (Thiebaud et al., 1990).
This agent has been considered effective for
HHM, but there are few reports on the efficacy
of HHM with ovarian cancer.  Serum dihy-
droxyvitamin D (1,25-DHD) concentrations are
commonly low in patients with HHM.  How-
ever, the concentration of 1,25-DHD was high
in this case.
We present an ovarian adenocarcinoma
patient with HHM who underwent successful
management with bisphosphonate pamidronate.
Additionally, PTHrP metabolism including
1,25-DHD was investigated.
Patient Report
A 54-year-old postmenopausal woman, gravida
0, presented herself to Tottori University Hos-
pital on August 30, 1995.  She had a 4-week his-
tory of lower abdominal pain, constipation,
nausea, general malaise and a loss of weight of
5 kg.  Upon presentation, her weight was 43 kg,
height, 148 cm, pulse rate, 72 beats/min and
regular, and blood pressure, 106/70 mmHg.  A
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Table 1.  Biochemical data of bone and mineral metabolism before therapy
Laboratory findings Measured values Normal values
Serum Calcium (mg/dL) 16.8 8.6 – 11
Phosphate (mg/dL) 1.1 3 – 5
Creatinine (mg/dL) 0.7 0.6 – 1.6
Alkaline phosphatase (IU/L) 259 111– 295
Alkaline phosphatase isozyme 3 (%) 28 29 – 62
Osteocalcin (ng/mL) 4.9 2.5 – 13
PTH-intact (pg/mL) < 2.0 6.5 – 59.7
PTHrP-intact (pmol/L) 10 < 1.1
1,25-DHD (pg/mL) 104 20 – 60
25-Hydroxyvitamin D (ng/mL) 10 10 – 55
24,25-DHD (ng/mL) 1.2 1.8 – 3.8
Urine Calcium (mg/dL) 21.3 5.3 – 30
Phosphate (g/day) 0.72 0.3 – 2.2
Nephrogeneous cyclic AMP (µmol/day) 4.8 1.8 – 6.3
Pyridinoline (µmol/molCr) 120 13 – 36
Deoxypyridinoline (µmol/molCr) 16 < 7
DHD, dihydroxyvitamin D; PTH, parathyroid hormone; PTHrP, PTH-related protein.
solid ovarian tumor with a diameter of 8 cm in
its greatest dimension revealed by computed
tomography was observed in the lower abdo-
men.  Serum levels of CA125 and small cell
cancer were slightly elevated to 120 U/mL
(normal range < 35 U/mL) and 1.7 ng/mL (normal
range < 1.5 ng/mL), respectively.  The serum
calcium concentration increased to 16.8 mg/dL.
Biochemical examination revealed that her
urinary calcium excretion, cyclic AMP, alcohol
dehydrogenase and free T3 were within normal
ranges, but that the serum phosphate extremely
decreased and the 1,25-DHD increased to 104
pg/mL.  PTHrP-intact was elevated to 10.0
pmol/L (PTHrP C-terminal 442 pg/mL).  On the
other hand, parathyroid hormone (PTH)-intact
fell to < 2.0 pg/mL, (PTH C-terminal < 0.6 ng/
mL).  Biochemical data are shown in Table 1.
The bone mineral density of the spine measured
by dual energy X-ray absorptiometry was in the
normal range.  Whole body computed tomogra-
phy, X-ray, and bone scintigram revealed no
evidence of bone metastasis.
The serum calcium concentration raised to
16.8 mg/dL and an abnormal electrocardiogram
reading due to hypercalcemia (shortened QT)
was observed.  For the treatment of hyper-
calcemia, 45 mg of bisphosphonate pamidro-
nate was injected intravenously over a 240-min
period on October 25.  After the treatment,
serum calcium decreased to 8.5 mg/dL.  As a
result, her complaints, such as nausea, vertigo,
drowsiness, arrhythmia and muscle pain, dis-
appeared.
On October 31, laparotomy was carried out,
but it was judged impossible to achieve optimal
operation criteria, because of the presence of a
residual tumor mass smaller than 2 cm, so an
omentectomy was performed without bowel
resection.  A biopsy specimen from the left
ovarian tumor revealed a grade-1 adenocarci-
noma (Fig. 1).  Under diagnosis of stage IIIb
ovarian cancer, she underwent chemotherapy
consisting of a combination of 50-mg/m2
cisplatin, 40-mg/m2 adriamycin and 400-mg/m2
cyclophosphamide.  Serum calcium was well
controlled by bisphosphonate pamidronate, and
hydration with 3000 mL/day of saline and furo-
semide.  In spite of 2 courses of chemotherapy,
the tumor increased to 166% in the size of the
measurable lesion.  We conducted 2nd surgery
consisting of total hysterectomy, bilateral
salpingo-oophorectomy, retroperitoneal lymph-
adenectomy including the para-aortic nodes.
On December 26, she underwent 2nd surgery
and a segment of the sigmoid colon and the
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Fig. 1.  Photomicrograph of cancer tissues.  A: Low magnification.  There is papillary
proliferation of cancer cells (hematoxylin and eosin stain).  Original magnification, × 40.  B:
High magnification (hematoxylin and eosin stain).  Original magnification, × 200.
rectum were removed to achieve optimal tumor
resection.  After this surgery, serum calcium,
PTHrP and 1,25-DHD fell to normal limits
without other therapy.  PTH was recovered 2
months later (Fig. 2).  Tissue diagnosis showed
adenocarcinoma.  The histochemical examina-
tion of PTHrP using the anti-human mono-
clonal antibody, 4B3, showed positive staining
in tumor cells (Fig. 3) (Kitazawa et al., 1991).
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PTHrP-intact (pmol/L) 10.0 10.0 < 1.1 < 1.1
PTH-intact (pg/mL) < 2.0 < 2.0 2.3 8.8
1,25-DHD (pg/mL) 104 86 39.5 38.1
CA125 (U/mL) 120 72 6 3
2nd CAP
Hydration (3000 mL/day), furosemide







Fig. 2.  Treatment and changes of calcium, PTHrP-intact, PTH-intact and CA125.  BP, bisphosphonate
pamidronate; CAP, cisplatin, adriamycin and cyclophosphamide; EP, etoposide and cisplatin.
Fig. 3.  Immunohistochemical demonstration of PTHrP production by the tumor.  Positive
staining is shown in the cytoplasm of the cancer cells.  Original magnification, × 100.
She received 5 courses of post operative
chemotherapy consisting of 100-mg/body
etoposide daily from days 1 to 5 and 50-mg/m2
cisplatin on day 5.  She has had no evidence of
recurrence for 24 months.
Discussion
Several agents, such as prostaglandin, in-
terleukin 1, transforming growth factor (TGF)-
α, TGF-β and colony stimulating factor, have
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been reported as inducing HHM factor
(Bringhurst et al., 1986; Tashjian et al., 1986;
Sato et al., 1987; Linkhart et al., 1989).  These
are considered to be local factors of osteolytic
hypercalcemia.  In this case, since immuno-
histochemistry revealed the production of
PTHrP, PTHrP was causative for HHM.
PTHrP acted very similarly to the PTH, but
the clinical syndrome of HHM has distinct
differences from primary hyperparathyroidism.
For example, in HHM, an increase in bone re-
sorption is not coupled with increased bone
formation as in primary hyperthyroidism.  In
our case, bone mineral density and serum osteo-
calcin were in the normal range and urine
pyridinoline and deoxypyridinoline were high.
Additionally, serum 1,25-DHD concentrations
are commonly low in patients with HHM
(Schilling et al., 1993).  However, 1,25-DHD
concentration was extremely high in this case.
The concentration of 1,25-DHD is considered
to relate to renal function.  Most cases of HHM
have damage in renal function because of long-
standing hypercalcemia and so 1,25-DHD con-
centrations are low (Hoekman et al., 1991).  In
contrast, this case might have been in its early
stages and had normal renal function. There
was some possibility that several cytokines
produced by cancer cells and the low serum
phosphate may stimulate the renal 1α-hydroxy-
lase activity.
Since HHM has been commonly observed
in the end stages of malignancy, the prognosis
of this disease is poor.  Additionally, appropri-
ate management for HHM has been not estab-
lished.  Bisphosphonate pamidronate was effec-
tive in normalizing the serum calcium level of
hypercalcemic patients with malignancies
(Harinck et al., 1987).  However, the efficacy
for HHM was transient.  In our case, bisphos-
phonate pamidronate reduced serum calcium
levels, but the serum level of PTHrP did not de-
crease.  The management of HHM with bis-
phosphonate pamidronate is not easy, i.e.,
hydration is necessary to maintain urine flow
and a proper level of sodium chloride.  Our pa-
tient needed hydration with 3000 mL/day of
saline and furosemide.
In our case, the patient could undergo tumor
resection after the management of hyper-
calcemia with bisphosphonate pamidronate and
then have a good prognosis.
These results suggest that bisphosphonate
pamidronate may be useful for the management
of hypercalcemia, but this management should
be followed by radical treatment for HHM such
as tumor reduction for improving prognosis,
including the quality of life of patients with HHM.
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